Thyroid removal for Graves' disease or amiodarone-induced thyrotoxicosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will prospectively register adults undergoing thyroidectomy for Graves' disease or amiodarone-induced thyrotoxicosis in the EUROCRINE registry with an added module for study-specific routine data. It will compare surgical complication rates according to preoperative or perioperative thyroid metabolic status without changing standard preoperative, operative, or postoperative care. Collected data will include biochemical thyroid status, medications, surgical details, and postoperative outcomes across multiple European centers. The approach is registry-based and aims to identify whether patients who are not fully euthyroid at the time of surgery experience higher morbidity than those who are euthyroid.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (≥ 18 years of age) undergoing surgical treatment for Graves' disease or Amiodarone-induced thyrotoxicosis (AIT) with biochemically confirmed hyperthyroidism or on specific medication for the treatment of Graves' disease or AIT.
* Patients providing signed informed consent.

Exclusion Criteria:

* Children and minors (\<18 years).
* Pregnant women.
* Patients unable or unwilling to provide informed consent due to language barriers or intellectual limitations.
* Patients undergoing concurrent parathyroidectomy for primary or secondary hyperparathyroidism, lymph node clearance, or redo surgery.
* Surgical procedures performed for other reasons than Graves' disease or AIT

Where it's running

• OLV Ziekenhuis
  Aalst, Belgium Recruiting
• Universite de Lorraine, Cru Nancy
  Nancy, France Recruiting
• Evgenidion Hospital Athens
  Athens, Greece Recruiting
• Universitario Virgen de las Nieves
  Granada, Spain Recruiting
• Hospital Costa del Sol
  Marbella, Spain Recruiting
• Kantonsspital Winterthur
  Zurich, Winterthur, Switzerland Recruiting

Study contacts

• Principal investigator: Andrea Goldmann, MD — Kantonsspital Winterthur KSW
• Study coordinator: Andrea Goldmann, MD
• Email: andrea.goldmann@ksw.ch
• Phone: 052 266 21 21

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Efgartigimod for Graves' Disease in adults

  We are testing if efgartigimod given under the skin can help adults with Graves' disease by improving thyroid function and whether it is safe and tolerable.

  Recruiting at 35 sites Phase 3 argenx · Carlsbad, California and 34 other locations · NCT07570316

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Opioid-Free vs Opioid-Based Anesthesia for Thyroid Surgery

  This study tests whether a non-opioid anesthesia approach can match or improve outcomes for adults undergoing thyroidectomy.

  Recruiting Malatya Egitim Ve Arastirma Hastanesi · Malatya · NCT07864155

• Early risk stratification of thyroid eye disease in newly diagnosed Graves' disease

  This study tests whether early eye-related signs, blood and tear biomarkers, or eye surface features can predict who with Graves’ disease will develop thyroid eye disease within a year.

  Recruiting University of Copenhagen · Herlev · NCT07812194

• Felzartamab for Graves’ Disease: See if it helps control thyroids and reduce need for ATDs

  This study tests felzartamab vs placebo in adults with Graves’ disease to see if it can normalize thyroid hormones and let people stop anti-thyroid drugs.

  Recruiting at 14 sites Phase 2 Biogen · Glendale, Arizona and 13 other locations · NCT07722546

• AI-based MRI and ultrasound for thyroid-related eye disease

  This study tests an AI model using orbital MRI and eye ultrasound to help diagnose activity and severity of thyroid-associated ophthalmopathy and predict its course in adults.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Huangpu District · NCT07716397

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.